Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,894,528
  • Shares Outstanding, K 105,099
  • Annual Sales, $ 14,202 M
  • Annual Income, $ 4,413 M
  • EBIT $ 3,688 M
  • EBITDA $ 4,171 M
  • 60-Month Beta 0.31
  • Price/Sales 4.85
  • Price/Cash Flow 14.33
  • Price/Book 2.22

Options Overview Details

View History
  • Implied Volatility 31.45% ( -0.61%)
  • Historical Volatility 39.42%
  • IV Percentile 12%
  • IV Rank 19.41%
  • IV High 60.01% on 04/08/25
  • IV Low 24.58% on 11/13/24
  • Put/Call Vol Ratio 0.41
  • Today's Volume 553
  • Volume Avg (30-Day) 2,076
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 55,983
  • Open Int (30-Day) 57,570

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 8.29
  • Number of Estimates 7
  • High Estimate 10.82
  • Low Estimate 6.92
  • Prior Year 9.90
  • Growth Rate Est. (year over year) -16.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
541.00 +26.95%
on 10/13/25
690.48 -0.53%
on 11/12/25
+122.18 (+21.64%)
since 10/10/25
3-Month
541.00 +26.95%
on 10/13/25
690.48 -0.53%
on 11/12/25
+130.26 (+23.40%)
since 08/12/25
52-Week
476.49 +44.14%
on 06/05/25
823.56 -16.60%
on 11/13/24
-134.19 (-16.34%)
since 11/12/24

Most Recent Stories

More News
Stocks Settle Mostly Higher on Government Reopening Optimism

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.31%. December E-mini...

AMAT : 230.41 (+0.76%)
AVGO : 355.73 (+1.07%)
MRK : 92.09 (+1.25%)
RGTI : 29.56 (-5.86%)
$IUXX : 25,460.61 (-0.29%)
AMGN : 340.02 (+0.46%)
PFE : 25.76 (+0.98%)
ELV : 328.13 (+4.09%)
ASML : 1,033.81 (+1.11%)
ZNZ25 : 113-000 (-0.03%)
CRWV : 88.60 (+0.24%)
VRTS : 164.83 (+0.57%)
Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks

Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks

REGN : 685.44 (+1.61%)
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results...

REGN : 685.44 (+1.61%)
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years and...

REGN : 685.44 (+1.61%)
5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call

5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call

REGN : 685.44 (+1.61%)
Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:  REGN ) will webcast management participation as follows: Jefferies London Healthcare Conference at 3:30...

REGN : 685.44 (+1.61%)
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions  First and only therapy to specifically target the...

REGN : 685.44 (+1.61%)
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29,...

OPK : 1.3150 (-1.13%)
REGN : 685.44 (+1.61%)
Stock Index Futures Gain on Nvidia Boost Ahead of Fed Rate Decision and Big Tech Earnings

December S&P 500 E-Mini futures (ESZ25) are up +0.19%, and December Nasdaq 100 E-Mini futures (NQZ25) are up +0.35% this morning, buoyed by ongoing tech and AI momentum, while investors await the Federal...

KLAC : 1,198.62 (+0.65%)
EQNR.O.DX : 244.200 (-1.77%)
NVDA : 192.84 (-0.17%)
GOOGL : 284.96 (-2.18%)
META : 609.53 (-2.80%)
CVS : 81.10 (+1.54%)
MDLZ : 57.48 (+0.63%)
BE : 123.79 (-2.58%)
VZ : 40.81 (+0.27%)
NQZ25 : 25,603.00 (-0.15%)
SWECB.S.DX : 167.800 (+0.84%)
MSFT : 500.99 (-1.51%)
REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage

REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage

REGN : 685.44 (+1.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 708.41
2nd Resistance Point 692.37
1st Resistance Point 683.46
Last Price 685.44
1st Support Level 658.51
2nd Support Level 642.47
3rd Support Level 633.56

See More

52-Week High 823.56
Fibonacci 61.8% 690.98
Last Price 685.44
Fibonacci 50% 650.02
Fibonacci 38.2% 609.07
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar